HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies
Francesco Bussu MD, PhD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorCorresponding Author
Luca Tagliaferri MD, PhD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Correspondence
Luca Tagliaferri, Polo Scienze Oncologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Largo Agostino Gemelli, 8, 00168 Roma, Italy.
Email: [email protected]
Search for more papers by this authorGiancarlo Mattiucci MD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Search for more papers by this authorClaudio Parrilla MD, PhD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
Search for more papers by this authorDavide Rizzo MD, PhD
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorMaria Antonietta Gambacorta MD, PhD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italia
Search for more papers by this authorValentina Lancellotta MD
Radiation Oncology, Universitá di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy
Search for more papers by this authorRosa Autorino MD, PhD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Search for more papers by this authorCarla Fonnesu MD
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorCaterina Kihlgren MD
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorJacopo Galli MD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
Search for more papers by this authorGaetano Paludetti MD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
Search for more papers by this authorGyörgy Kovács MD, PhD
Interdisciplinary Brachytherapy Unit, University of Lübeck and University Hospital S-H, Campus Lübeck, Germany
Search for more papers by this authorVincenzo Valentini MD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Search for more papers by this authorFrancesco Bussu MD, PhD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorCorresponding Author
Luca Tagliaferri MD, PhD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Correspondence
Luca Tagliaferri, Polo Scienze Oncologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Largo Agostino Gemelli, 8, 00168 Roma, Italy.
Email: [email protected]
Search for more papers by this authorGiancarlo Mattiucci MD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Search for more papers by this authorClaudio Parrilla MD, PhD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
Search for more papers by this authorDavide Rizzo MD, PhD
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorMaria Antonietta Gambacorta MD, PhD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italia
Search for more papers by this authorValentina Lancellotta MD
Radiation Oncology, Universitá di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy
Search for more papers by this authorRosa Autorino MD, PhD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Search for more papers by this authorCarla Fonnesu MD
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorCaterina Kihlgren MD
ENT Division, Azienda Ospedaliero Universitaria, Sassari, Italia
Search for more papers by this authorJacopo Galli MD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
Search for more papers by this authorGaetano Paludetti MD
Universitá Cattolica del Sacro Cuore, Istituto di Otorinolaringoiatria, Roma, Italia
Search for more papers by this authorGyörgy Kovács MD, PhD
Interdisciplinary Brachytherapy Unit, University of Lübeck and University Hospital S-H, Campus Lübeck, Germany
Search for more papers by this authorVincenzo Valentini MD
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italia
Search for more papers by this authorAbstract
Background
Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed.
Methods
Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases.
Results
Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%).
Conclusion
HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.
REFERENCES
- 1Aronowitz JN. Afterloading: the technique that rescued Brachytherapy. Int J Radiat Oncol Biol Phys. 2015; 92(3): 479-487.
- 2Lukens JN, Gamez M, Hu K, Harrison LB. Modern brachytherapy. Semin Oncol. 2014; 41(6): 831-847.
- 3Tagliaferri L, Kovács G, Autorino R, et al. ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy. 2016; 8(4): 336.
- 4Valentini V, Maurizi F, Tagliaferri L, et al. Spider: managing clinical data of cancer patients treated through a multidisciplinary approach by a palm based system. Ital J Public Health. 2012; 5(2): 154-164.
- 5Tagliaferri L, Bussu F, Fionda B, et al. Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: single-institution experience and systematic review. Tumori. 2017; 103(6): 516-524.
- 6Kupferman ME, Morrison WH, Santillan AA, et al. The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer. 2007; 109(10): 2052-2057.
- 7Bussu F, Tagliaferri L, Mattiucci G, et al. Comparison of interstitial brachytherapy and surgery as primary treatments for nasal vestibule carcinomas. Laryngoscope. 2016; 126(2): 367-371.
- 8Tagliaferri L, Bussu F, Rigante M, et al. Endoscopy-guided brachytherapy for sinonasal and nasopharyngeal recurrences. Brachytherapy. 2015; 14(3): 419-425.
- 9Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of Normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl): S3-S9.
- 10Nag S, Cano ER, Demanes DJ, Puthawala AA, Vikram B, American Brachytherapy S. The American Brachytherapy society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2001; 50(5): 1190-1198.
- 11Mazeron JJ, Ardiet JM, Haie-Meder C, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol. 2009; 91(2): 150-156.
- 12Kovacs G, Martinez-Monge R, Budrukkar A, et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update - improvement by cross sectional imaging based treatment planning and stepping source technology. Radiother Oncol. 2017; 122(2): 248-254.
- 13Pellizzon AC, Salvajoli JV, Kowalski LP, Carvalho AL. Salvage for cervical recurrences of head and neck cancer with dissection and interstitial high dose rate brachytherapy. Radiat Oncol. 2006; 1: 27.
- 14Syed AM, Feder BH, George FW III. Persistent carcinoma of the oropharynx and oral cavity re-treated by after-loading interstitial 192Ir implant. Cancer. 1977; 39(6): 2443-2450.
10.1002/1097-0142(197706)39:6<2443::AID-CNCR2820390622>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 15Vikram B, Strong EW, Shah JP, et al. Intraoperative radiotherapy in patients with recurrent head and neck cancer. Am J Surg. 1985; 150(4): 485-487.
- 16Glatzel M, Buntzel J, Schroder D, Kuttner K, Frohlich D. High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer. Laryngoscope. 2002; 112(8 Pt 1): 1366-1371.
- 17Strnad V, Lotter M, Kreppner S, Fietkau R. Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: long-term results. Strahlenther Onkol. 2015; 191(6): 495-500.
- 18Rudzianskas V, Inciura A, Vaitkus S, et al. Reirradiation for patients with recurrence head and neck squamous cell carcinoma: a single-institution comparative study. Medicina (Kaunas). 2014; 50(2): 92-99.
- 19Kolotas C, Tselis N, Sommerlad M, et al. Reirradiation for recurrent neck metastases of head-and-neck tumors using CT-guided interstitial 192Ir HDR brachytherapy. Strahlenther Onkol. 2007; 183(2): 69-75.
- 20Hepel JT, Syed AM, Puthawala A, Sharma A, Frankel P. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005; 62(5): 1444-1450.
- 21Hazkani I, Rabinovics N, Limon D, et al. Brachytherapy for radiotherapy-resistant head and neck cancer: a review of a single center experience. Laryngoscope. 2016; 126(10): 2246-2251.
- 22Wan XB, Jiang R, Xie FY, et al. Endoscope-guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma. PLoS One. 2014; 9(3): e90048.
- 23Teudt IU, Kovacs G, Ritter M, et al. Intensity modulated perioperative HDR brachytherapy for recurrent and/or advanced head and neck metastases. Eur Arch Otorhinolaryngol. 2016; 273(9): 2707-2715.
- 24Bussu F, Gallus R, Navach V, et al. Contemporary role of pectoralis major regional flaps in head and neck surgery. Acta Otorhinolaryngol Ital. 2014; 34(5): 327-341.
- 25Wang CC. Treatment of carcinoma of the nasal vestibule by irradiation. Cancer. 1976; 38(1): 100-106.
10.1002/1097-0142(197607)38:1<100::AID-CNCR2820380118>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 26Horsmans JD, Godballe C, Jorgensen KE, Bastholt L, Lontoft E. Squamous cell carcinoma of the nasal vestibule. Rhinology. 1999; 37(3): 117-121.
- 27Vital D, Morand G, Huber GF, Studer G, Holzmann D. Outcome in squamous cell carcinoma of the nasal vestibule: a single center experience. Head Neck. 2015; 37(1): 46-51.
- 28Jeannon JP, Riddle PJ, Irish J, O'sullivan B, Brown DH, Gullane P. Prognostic indicators in carcinoma of the nasal vestibule. Clin Otolaryngol. 2007; 32(1): 19-23.
- 29Levendag PC, Nijdam WM, van Moolenburgh SE, et al. Interstitial radiation therapy for early-stage nasal vestibule cancer: a continuing quest for optimal tumor control and cosmesis. Int J Radiat Oncol Biol Phys. 2006; 66(1): 160-169.
- 30Lipman D, Verhoef LC, Takes RP, Kaanders JH, Janssens GO. Outcome and toxicity profile after brachytherapy for squamous cell carcinoma of the nasal vestibule. Head Neck. 2015; 37(9): 1297-1303.
- 31Vanneste BG, Lopez-Yurda M, Tan IB, Balm AJ, Borst GR, Rasch CR. Irradiation of localized squamous cell carcinoma of the nasal vestibule. Head Neck. 2016; 38(Suppl 1): E1870-E1875.
- 32Kovács G, Tagliaferri L, Valentini V. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachytherapy. 2017; 9(6): 497-498.
Citing Literature
